💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Sahajanand Medical Technologies Limited is a medical devices company engaged in the development and manufacturing of advanced cardiovascular implants, including vascular intervention and structural heart products.
| Day | QIB | NII | Retail | Total |
|---|---|---|---|---|
| Day 1 · 15 Oct | 0.00× | 0.14× | 0.21× | 0.13× |
| Day 2 · 16 Oct | 0.00× | 0.31× | 0.44× | 0.28× |
QIB = qualified institutional buyers, NII = non-institutional (HNI) investors, Retail = individual bids up to ₹2 lakh. Figures are end-of-day captures; the final day's number can rise further after 5 PM as the exchange consolidates bids.
The company is a Class III and Class C/D medical devices player with a portfolio focused on vascular intervention and structural heart products, including drug-eluting stents, PTCA balloons, TAVI systems, and occluders.
Founded in 2001, the company operates R&D centers in India and Thailand and maintains integrated manufacturing facilities, supported by a global presence across 77 countries as of Fiscal 2026.
Only the fresh-issue half funds the company. Offer-for-sale money goes to shareholders selling out — it changes who owns the business, not what the business can spend.
Since its listing-day close it has moved +29.1%, while the Nifty moved +8.6% over the same 9 sessions. Windows are measured vs the issue price and fill in as sessions trade.
Full stock analysis for SMT →At the upper band of ₹344 and FY26 diluted EPS of ₹6.48, the issue is priced at 53.1× earnings; the listed peers named in the RHP range from 36.4× to 51.4× (average 43.9×).
Peer multiples are as printed in the RHP (priced on its record date) and differ in size, growth and quality — a P/E comparison describes where the price sits, not whether it is right. Not a recommendation.
This row was written the day before listing and has not been edited since. Right or wrong, it stays.
An issue price only means something next to what the market already pays for similar businesses.
GMP is unofficial, unregulated grey-market chatter. It moves hourly, it is not a quoted price, and listing prices routinely diverge from it. Nothing on this page is a recommendation to apply for or avoid this issue — it is the public record plus a description of the business, published for education. The business profile is an AI summary of the company's red herring prospectus; every figure shown was checked to appear in the prospectus text, and anything that didn't match was left out. Read the RHP itself before relying on any of it.
Sahajanand Medical Technologies listed on 23 Oct 2026 at Rs 371 against an issue price of Rs 344 — a gain of 7.9% on debut.
The Sahajanand Medical Technologies IPO price band is Rs 327 to Rs 344 per share, with bidding open from 15 Oct 2026 to 19 Oct 2026. It is a Mainboard issue.
The minimum bid is one lot of 43 shares, which is Rs 14,792 at the upper price band. A retail investor can bid for up to 13 lots (Rs 1,92,296) within the Rs 2 lakh retail limit.
As of 5 Nov 2026, Sahajanand Medical Technologies traded 41.8% above its issue price and 29.1% above its listing-day close; the Nifty moved +8.6% over the same period.
At the upper price band of Rs 344 and diluted EPS of Rs 6.48 (FY2026), the Sahajanand Medical Technologies IPO is priced at about 53.1 times earnings. The listed peers named in its RHP trade between 36.4x and 51.4x (average 43.9x). A P/E comparison describes where the price sits relative to peers; it is not a recommendation.
As of 16 Oct 2026, the Sahajanand Medical Technologies IPO was subscribed 0.28 times overall — QIB 0.00 times, NII 0.31 times, retail 0.44 times, per official NSE bid data.
Across the 47 IPO listings this tracker has scored, the grey market premium called the listing direction correctly 83% of the time, missing the size of the move by a median 6.6 percentage points. Each final GMP is frozen the day before listing and scored publicly against the actual debut.
Trade Edge AI does not make apply/avoid calls — it is not a SEBI-registered Investment Adviser or Research Analyst. This page publishes the public record (issue details, GMP history, listing outcome) and a plain description of the business so you can make your own decision; read the RHP and consult a SEBI-registered adviser.